NYSE: OSTX · Life Sciences · 3 alerts · CIK 1795091
Share price
$0.6807Close, Nov 16
Market cap
$35.6M
Shares outstanding
52.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All OS Therapies Inc filings on SEC EDGAR ↗
OS Therapies received a VAT refund of approximately $900,000 from the U.K. tax authority (HMRC) to support the development of its lead product candidate, Herlystic. The company also clarified that the FDA's suspension of the Commissioner’s National Priority Voucher program does not impact the candidate's eligibility for the transferable rare pediatric disease priority review voucher program.
OS Therapies announced the initial closing of a warrant exercise inducement and exchange offer, raising $7.2 million in gross proceeds from seven accredited investors. Participating holders exercised warrants at a reduced price of $1.30 per share in exchange for new warrants to purchase an equal number of shares at $1.40. The proceeds will fund regulatory filings and commercial preparation for Herlystic™ in the U.S., U.K., EU, and Australia.
OS Therapies appointed Frank Knuettel II as Chief Financial Officer and Kerry Clem as Chief Commercial Officer, effective September 29, 2026. Mr. Knuettel succeeds Christopher P. Acevedo, who will transition to a consulting role, while Mr. Clem will lead the commercialization strategy for the company's lead product candidate, Herlystic.